On October 14, 2026, the FDA submitted a document to the White House Office of Management and Budget titled "Interim Access Policy for Compounding Using Certain Peptides."

The official regulatory tracker (OIRA, RIN 0910-ZD94) confirms:

Received: October 14, 2026
Stage: Notice
Status: Pending review
Legal deadline: None

This is the most significant peptide regulatory development in years.

It is also, as of today, not a rule. Not a law. Not a permission. Not an approval.

This post explains what it is, what it would mean if finalized, what it would not mean regardless, and why those two things are not the same.

What Actually Happened

The FDA developed a policy document and submitted it to the White House for review.

The White House Office of Information and Regulatory Affairs (OIRA) reviews significant regulatory actions before they take effect. The submission is a procedural step in the rule-making process — not the end of it.

The policy text has not been published. No one outside the government has read the specific language of what's being proposed. AP reported, citing people familiar with the confidential proposal, that the policy involves temporary enforcement discretion for certain compounded peptides including BPC-157. Reuters confirmed the filing but noted the public OIRA record contains no policy details.

Until the text is published, the contents are what confidential sources describe them to be.

What We Know About the Expected Policy

The policy text is not public. What follows is what has been reported or can be inferred from the record.

The six compounds the advisory committee recommended (which ones the policy covers has not been disclosed):

BPC-157
KPV
TB-500 (Thymosin Beta-4)
MOTS-c
Epitalon
Semax

These are the same six compounds the FDA's Pharmacy Compounding Advisory Committee (PCAC) recommended for potential 503A inclusion at its July 23-24, 2026 meeting. Emideltide (DSIP) — the seventh compound reviewed — was rejected.

Likely 503A focus. Reporting describes access through state-licensed compounding pharmacies, following PCAC votes on the 503A Bulks List. Whether 503B outsourcing facilities are covered has not been made public. Research-use-only vendors and supplement sellers are outside any compounding policy.

Enforcement discretion, not the Bulks List. AP reported the policy would rely on enforcement discretion. Holland & Knight (October 16, 2026) expects interim enforcement discretion — for example, moving the peptides into Category 1 of FDA's interim bulks policy — while formal rulemaking continues. Covered peptides would remain unapproved drugs.

A second PCAC meeting is planned by end of February 2027 to review five additional compounds: GHK-Cu, LL-37, Dihexa, melanotan II, and PEG-MGF.

What Enforcement Discretion Means

Enforcement discretion is an administrative tool. It means the agency temporarily chooses not to prioritize enforcement of certain rules against certain activities, under stated conditions.

What it is:

A temporary, conditional agreement not to take enforcement action against qualifying 503A pharmacies compounding the specified peptides
Revocable without formal rulemaking — the agency can withdraw enforcement discretion faster than it can change a rule

What it is not:

FDA approval of the compounds as safe and effective for any indication
An addition to the 503A Bulks List (which requires formal notice-and-comment rulemaking)
A finding that the compounds have been adequately studied in humans
A guarantee against future enforcement if conditions change

The fastest instrument available for expanding access is also the fastest instrument for withdrawing it.

What Would Not Change Even If the Policy Publishes

The evidence problem doesn't change.

At the July 2026 PCAC meeting, FDA staff opposed adding the peptides, citing insufficient clinical evidence of safety and effectiveness. BPC-157 was reviewed for ulcerative colitis; FDA said the evidence did not support that use, that there was not enough information to know whether it would cause harm in humans, and that approved drugs already treat the condition.

The PCAC voted 8-6, with one abstention, to recommend BPC-157 anyway. Advisory committee votes are nonbinding.

A legal pathway created by enforcement discretion does not retroactively generate the clinical trials that FDA staff said were missing. It does not resolve the evidence questions. It creates a supervised channel for access to compounds that remain, as of today, largely unstudied in controlled human trials.

The supply chain problem doesn't change.

The same day the filing was first reported, Bloomberg reported that FDA inspectors had found black mold on equipment, insects in ceiling voids, and falsified laboratory records at two Chinese factories making GLP-1 API for US compounding pharmacies. Both facilities are now on the FDA import-alert list.

A policy that allows 503A pharmacies to compound BPC-157 does not automatically improve the quality or traceability of the BPC-157 API those pharmacies will use. It creates a legal framework; it does not create a verified supply chain.

The three-question test still applies.

Regardless of what any policy says, the questions that determine whether a specific product is safe for a specific person remain:

Does the molecule have adequate human evidence of benefit?
Is the specific product authenticated, sterile, and correctly dosed?
Has it been demonstrated safe for this person's specific situation?

A legal lane answers none of these. It settles a different question — whether a pharmacy may compound the substance — and leaves the evidence, product and patient questions open.

The Timeline So Far

Date	Event
April 15, 2026	FDA gave notice that 12 peptides would leave Category 2 (significant safety risks) after their nominations were withdrawn; none was added to any list
July 23-24, 2026	FDA staff opposed the peptides; PCAC voted to recommend six of seven (BPC-157 8-6 with one abstention; emideltide rejected)
October 14, 2026	FDA submitted interim access policy to OIRA for White House review
By end of February 2027	Second PCAC planned for GHK-Cu, LL-37, Dihexa, melanotan II, PEG-MGF

Current status: OIRA review pending. No policy text published. No effective date announced. No pharmacy has new compounding authority.

What to Watch For

When (and if) the policy text publishes, the specific questions to answer:

Which exact compounds and forms (sterile injectable? oral? topical?) are covered?
What prescribing conditions apply? Does a valid patient-specific prescription from a licensed prescriber remain required?
What sourcing and testing requirements must the 503A pharmacy meet?
What patient disclosure requirements apply?
What adverse-event reporting is required?
What is the effective date, and how long does the enforcement discretion last?
What triggers withdrawal of the discretion?

Until that text exists, no claim about what is or isn't permitted is supportable. Not by a vendor, not by a clinic, not by anyone.

The Right Framing

The correct headline for this week: "FDA peptide policy enters White House review."

The incorrect headlines you will see: "FDA legalizes peptides." "BPC-157 is now FDA-approved." "Peptides are finally legal."

Those headlines will run. The contrast between accurate and inaccurate coverage of this development is itself a story about how the category works.

A legal lane and a vetted lane are not the same thing. The first is a regulatory decision. The second is built one clinical trial at a time.

Sources

OIRA official review record, RIN 0910-ZD94. reginfo.gov.
Reuters, "US FDA takes step to change peptide compounding policy," October 15, 2026.
Associated Press, October 15, 2026, citing two people familiar with the policy.
Holland & Knight, "Peptides at a Crossroads: What Wellness Providers Need to Know," October 16, 2026.
Orrick, "FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings," April 16, 2026.
McDermott, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting," July 27, 2026.
FDA, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026. fda.gov.
Bloomberg (FOIA), "Black Mold, Bugs Found at Chinese Plants Making GLP-1 Compounding Agents," October 15, 2026.

PeptidesGPT is an educational platform. This content does not constitute legal or medical advice. The policy described in this post has not been published or implemented as of the publication date. Nothing in this post should be construed as a statement that any compound is currently permitted for compounding, or that any clinical benefit has been established. Consult a licensed healthcare provider for individualized medical guidance.

A Legal Lane and a Vetted Lane Are Not the Same Thing: What the FDA Peptide Policy Filing Actually Means